BIRDEM General Hospital, Bangladesh
BIRDEM General Hospital, Bangladesh
BIRDEM General Hospital, Bangladesh
BIRDEM General Hospital, Bangladesh
BIRDEM General Hospital, Bangladesh
* Corresponding author
BIRDEM General Hospital, Bangladesh
BIRDEM General Hospital, Bangladesh
BIRDEM General Hospital, Bangladesh

Article Main Content

Antibody titer study is very important to assess the degree of undetected transmission in the community. This study aimed to estimate the antibody response to SARS-CoV-2 infection in a group of asymptomatic female workers and compare the clinical and socio-demographic parameters of seropositive and seronegative subjects in Bangladesh. This cross-sectional descriptive study was conducted among 285 female workers who had come to BIRDEM General Hospital for the COVID-19 test in November 2021 from different areas of Bangladesh.  RBD-specific antibody responses against SARS-CoV-2 were measured by using Chemiluminescent Microparticle Immunoassay (CMIA) for all participants. Overall antibody positivity was estimated at 91.9% (262), and only 8.1% of participants had a negative IgG antibody response. Of the 262 participants 96.18% were asymptomatic. In the age group, the highest seropositivity was between 21-30 years (58%). The median IgG titer of the antibody was estimated at 578.50 AU/ml. The participants of Khulna had the highest median IgG titer of 3966 AU/ml followed by other areas (p=0.043). There was no significant difference in median IgG titer in symptomatic, asymptomatic, and vaccinated, non-vaccinated participants. Based on the geographical area Dhaka and Barisal had significantly more seropositive subjects than seronegative subjects (p = 0.001) and (p = 0.011). The high number of undiagnosed COVID-19 patients in the population is reflected in the percentage of seropositive people. Our findings will assist academics in better understanding immune status and policymakers in taking proactive measures during pandemic situations and future health emergencies.

References

  1. Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020; 91(1): 157-160.
     Google Scholar
  2. Saha P, Gulshan J. Systematic Assessment of COVID-19 Pandemic in Bangladesh: Effectiveness of Preparedness in the First Wave. Front Public Health. 2021; 9: 628931.
    DOI  |   Google Scholar
  3. WHO. Coronavirus Disease (COVID-19) Dashboard, 2023. [Internet] [updated 2023 January 15; cited 2023 January 15]. Available from: https://covid19.who.int/
     Google Scholar
  4. Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020; 56(2): 106054.
    DOI  |   Google Scholar
  5. Callaway E, Cyranoski D, Mallapaty S, Stoye E and Tollefson J. The coronavirus pandemic in five powerful charts. Nature. 2020; 579(7800): 482-483.
    DOI  |   Google Scholar
  6. Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020; 396(10262): 1595-1606.
    DOI  |   Google Scholar
  7. Wu LP, Wang NC, Chang YH, Tian XY, Na DY, Zhang LY, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerging Infectious Diseases. 2007; 13(10): 1562-1564.
    DOI  |   Google Scholar
  8. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, Al Nsour M, et al. Persistence of Antibodies against the Middle East Respiratory Syndrome Coronavirus. Emerging Infectious Diseases. 2016; 22(10): 1824-1826.
    DOI  |   Google Scholar
  9. Fergie J, Srivastava A. Immunity to SARS-CoV-2: Lessons Learned. Frontiers in Immunology. 2021; 12: 654165.
    DOI  |   Google Scholar
  10. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine. 2020; 26(6): 845-848.
    DOI  |   Google Scholar
  11. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2020; 15(12): e0244126.
    DOI  |   Google Scholar
  12. Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody Responses in COVID-19: A Review. Front Immunol. 2021; 12: 633184.
    DOI  |   Google Scholar
  13. Shirin T, Bhuiyan TR, Charles RC, Amin S, Bhuiyan I, Kawser Z, et al. Antibody responses after COVID-19 infection in patients who are mildly symptomatic or asymptomatic in Bangladesh. Int J Infect Dis. 2020; 101: 220-225.
    DOI  |   Google Scholar
  14. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID- 19 and SARS, and uninfected controls. Nature. 2020; 584: 457-462.
    DOI  |   Google Scholar
  15. Akter A, Ahmed T, Tauheed I, Akhtar M, Ara SI, Qadri F. Disease characteristics and serological responses in patients with differing severity of COVID-19 infection: A longitudinal cohort study in Dhaka, Bangladesh. PLOS Neglected Tropical Diseases. 2022; 16(1): e0010102.
    DOI  |   Google Scholar
  16. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020; 7(1): 11.
    DOI  |   Google Scholar
  17. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). Treasure Island (FL): StatPearls Publishing. [Internet] [updated 2022 Jun 30; cited 2023 Jan 15] Available from https://pubmed.ncbi.nlm.nih.gov/32150360/
     Google Scholar
  18. WHO. “Immunity passports” in the context of COVID-19. [Internet] 2020 [updated 2020 April 24; cited 2023 Jan 15] Available from https://www.who.int/newsroom/commentaries/detail/immunity-passports-in-the-context-of-covid-19.
     Google Scholar
  19. Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y, et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. 2020; 115(6): 488-494.
    DOI  |   Google Scholar
  20. Khan AN and Ullah MR. Export scenario between Bangladesh and China: Opportunities of Bangladesh in RMG Sector. Eur Sci J. 2017; 13(28): 299-320.
    DOI  |   Google Scholar
  21. Hosen MS, Nafiujjaman M and Biswas FN. Garment employees are at higher risk than any other workers in COVID-19 pandemic in Bangladesh. Caspian Journal of Health Research. 2020; 5(1): 1-2.
    DOI  |   Google Scholar
  22. Cdc.gov. Dyal JW, Michael P, Michelle A. John D, Christa H, Fischer M, et al. COVID-19 among workers in meat and poultry processing facilities-19 states, April 2020. MMWR. Morbidity and mortality weekly report. 2020; 69.
     Google Scholar
  23. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26: 1200-1204.
    DOI  |   Google Scholar
  24. Lei Q, Li Y, Hou HY, Wang F, Ouyang ZQ, Zhang Y, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy. 2021; 76(2): 551-561.
    DOI  |   Google Scholar


Most read articles by the same author(s)